
The study analyzed BRD9 expression in TGCT tissues and cell lines, revealing its heterogeneous presence. BRD9 inhibition reduced cell viability, induced apoptosis, and caused G1-phase arrest. Transcriptomic analysis showed pluripotency loss and epithelial differentiation. These findings suggest BRD9 as a potential therapeutic target for cisplatin-resistant TGCT, providing hope for improved treatment options.
Like
Save
Share